This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SLC9A1 / Sodium/hydrogen exchanger 1 · IHC design guide
Design Immunohistochemistry for SLC9A1
Plan SLC9A1 paraffin IHC around membranous staining, with high signal in kidney collecting ducts and several glandular tissues (HPA tissue IHC). This guide covers fixation consistency, epitope placement and cell-specific scoring (standard IHC practice; UniProt topology; HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SLC9A1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Membranous in tissue (HPA tissue IHC); basolateral in most epithelia (UniProt) | |
| Staining pattern | Membranous in renal tubules and glandular cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet PB9151) | |
| Positive control | Colon+4 more · see all | |
| Negative control | Bone marrow+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Kidney staining is high in collecting ducts (HPA tissue IHC) | |
| Regulation | Expression regulation not specified (UniProt) | |
| Isoform / epitope | 2 isoforms; map the epitope to extracellular or cytoplasmic regions (UniProt) |
Section 1
Recommended SLC9A1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by one published SLC9A1 IHC protocol (PMC12605240).
| Sample | Paraffin-embedded rat kidney tissue; fixative not specified (datasheet PB9151) |
| Fixation | Image fixative and duration unreported (datasheet PB9151); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet PB9151); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PB9151) |
| Primary antibody | Rabbit anti-SLC9A1, 0.5-1μg/ml recommended; image 2 μg/ml (datasheet PB9151) |
| Primary incubation | Overnight at 4 °C (datasheet PB9151) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PB9151) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SLC9A1-positive staining in glandular cells of colon (HPA tissue IHC: High). HPA tissue profile: Membranous expression in several tissues, highly abundant in renal tubules, intestines, gallbladder, salivary gland and seminal gland. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet: PB9151); the published protocol does not state a retrieval method (PMC12605240).
Section 2
What Is the Expected SLC9A1 Staining Pattern?
SLC9A1 is a 13-pass plasma-membrane protein, localized basolaterally in epithelial cells except in choroid plexus, where it is luminal (UniProt P19634 topology and subcellular location). In paraffin-section IHC, expect membranous staining in renal collecting ducts and glandular cells of the intestine, gallbladder, and salivary gland (HPA: High; membranous tissue profile). HPA rates its tissue IHC pattern Enhanced, reflecting high consistency between staining and RNA expression (HPA: reliability).
| Distinct membrane outlines in renal collecting ducts or intestinal glandular cells, with little staining away from cell borders. | This fits a positive SLC9A1 result: both cell populations stain at High levels in HPA tissue IHC, and membrane localization agrees with UniProt P19634. In epithelial cells, assess the basolateral contour where section orientation permits; a partial outline can reflect which membrane surfaces the section exposes (UniProt P19634 subcellular location; standard IHC interpretation). |
| Predominantly nuclear or diffuse cytoplasmic chromogen, without convincing membrane staining in expected positive cells. | Treat this as a compartment mismatch and investigate background or antibody specificity before scoring it positive (UniProt P19634: cell membrane; HPA: membranous tissue profile). HPA reports an uncertain additional nucleoplasmic location in ICC-IF; that observation alone does not establish a predominantly nuclear paraffin-section IHC pattern (HPA: subcellular ICC-IF). |
| Strong staining in HPA-negative cell populations, such as bone-marrow hematopoietic cells or lung alveolar cells. | That distribution conflicts with the cited HPA tissue IHC observations of Not detected in those particular cell populations (HPA: bone marrow hematopoietic cells; lung alveolar cells). Consider cross-reactivity or endogenous chromogenic detection activity, then compare with staining in a known-positive tissue and appropriate detection controls (standard IHC practice). |
| Uniform haze across cells and extracellular areas obscures membrane borders. | A field-wide deposit does not support a compartment call, even when the section contains an HPA-positive tissue (HPA: membranous tissue profile; standard IHC interpretation). Review blocking, antibody concentration, washing, and detection background with controls before interpreting intensity; haze can conceal a genuine membrane signal or mimic weak widespread staining (standard IHC practice). |
| No visible staining in renal collecting ducts or colon glandular cells. | Both are High in HPA tissue IHC, so an absent signal warrants a technical check before concluding that this preparation lacks SLC9A1 (HPA: kidney collecting ducts; colon glandular cells). Confirm tissue identity and preservation, antibody application, detection reagents, and a positive control; HPA tissue levels do not establish a target-specific fixation effect (standard IHC practice; HPA: tissue IHC). |
💡Expected SLC9A1 appearanceCall the IHC result positive when clear, predominantly basolateral membrane staining marks the expected epithelial cells, typically strongly in renal collecting ducts or intestinal glandular cells; isolated nuclear staining or widespread haze without membrane definition is suspect (UniProt P19634 subcellular location; HPA: High in kidney and intestine; HPA: membranous tissue profile).
| Membrane polarity | UniProt places SLC9A1 basolaterally in epithelial cells, with a luminal choroid-plexus exception (UniProt P19634 subcellular location). Read membrane position in the context of tissue orientation; an apparently incomplete rim need not mean absence from the cell (standard IHC interpretation). |
| Tissue and cell selection | HPA reports High staining in kidney collecting ducts and glandular cells of colon, duodenum, gallbladder, and salivary gland; it reports Low staining in pancreatic exocrine glandular cells (HPA: tissue IHC). Specify the cell population when choosing controls or comparing intensity across tissues. |
| Epitope location | SLC9A1 has 13 transmembrane segments, extracellular loops, and a long cytoplasmic C-terminal region (UniProt P19634 topology). The supplied record does not identify this antibody's epitope, so topology cannot predict its staining strength or an antigen-retrieval setting. |
| Antibody validation | HPA lists Enhanced IHC validation for HPA048532, HPA052891, and CAB022371; its Enhanced tissue reliability reflects agreement between staining and RNA data (HPA: antibodies; tissue IHC reliability). Validation supports the reported distribution but does not make every unexpected signal specific. |
| IF/ICC: what location should be expected? | The supported main ICC-IF location is the plasma membrane; an additional nucleoplasmic location is marked uncertain (HPA: subcellular ICC-IF). Use that distinction when comparing images with IHC, without treating the uncertain nuclear signal as a required positive pattern. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive tissue is blank. | A failed staining or detection step is possible; HPA reports High staining in kidney collecting ducts and colon glandular cells (HPA: tissue IHC). | Check that the expected cells are present, then verify antibody application, reagent activity, and the positive control before interpreting the blank slide (standard IHC practice). |
| Staining is cytoplasmic but membrane borders are absent. | The compartment differs from the reported membrane localization (UniProt P19634; HPA: tissue IHC profile). | Inspect a well-oriented positive section and detection controls; score membrane localization separately from overall chromogen intensity (standard IHC practice). |
| Nuclei stain more strongly than cell borders. | Predominant nuclear IHC staining is unsupported by the tissue profile; HPA's additional nucleoplasmic ICC-IF location is uncertain (HPA: tissue IHC; subcellular ICC-IF). | Review controls and membrane staining before calling the result positive; record the nuclear signal as an unresolved finding (standard IHC interpretation). |
| HPA-negative cell populations stain strongly. | Cross-reactivity or endogenous detection activity may contribute; HPA reports Not detected in lung alveolar cells and bone-marrow hematopoietic cells (HPA: tissue IHC). | Compare a known-positive tissue with a control omitting primary antibody and check the chromogenic detection controls (standard IHC practice). |
| Diffuse brown background hides cell boundaries. | Excess nonspecific antibody or detection signal can prevent a membrane call (standard IHC practice). | Review blocking, antibody concentration, washing, and detection controls; reassess only where individual membrane borders remain visible (standard IHC practice). |
| A low-staining tissue appears weaker than the positive control. | HPA reports Low staining in pancreatic exocrine glandular cells versus High staining in renal collecting ducts (HPA: tissue IHC). | Compare like cell populations and retain a High-staining control; do not classify a weak low-expression population as assay failure on intensity alone (HPA: tissue IHC; standard IHC interpretation). |
Experiment evidence
IHC & IF images showing SLC9A1 staining
PB9151 · IHCIHC analysis of SLC9A1 using anti-SLC9A1 antibody (PB9151). SLC9A1 was detected in a paraffin-embedded section of rat kidney tissue. Heat me
PB9151 · IHCIHC analysis of SLC9A1 using anti-SLC9A1 antibody (PB9151). SLC9A1 was detected in a paraffin-embedded section of human mammary cancer tissu
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000090020-SLC9A1/tissue/cerebral+cortex#imid_17144023
HPA · StomachHuman Protein Atlas IHC, Stomach. Source: https://www.proteinatlas.org/ENSG00000090020-SLC9A1/tissue/stomach+1#imid_17143923
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000090020-SLC9A1/tissue/colon#imid_17143941
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000090020-SLC9A1/tissue/liver#imid_17143942
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA052891; green = SLC9A1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA052891; green = SLC9A1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SLC9A1 IHC & IF
🧪Run kidney first: collecting ducts must show staining because HPA rates them High (HPA: Kidney collecting ducts, High). Use bone marrow hematopoietic cells as the negative tissue (HPA: Bone marrow hematopoietic cells, Not detected); on the kidney slide, internal negative areas should show only counterstain or background, but other renal cell types should not be presumed negative from the supplied HPA row.
Positive control tissue: Colon (Glandular cells, HPA High)
Negative control tissue: Bone marrow (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SLC9A1 in A-431, MCF-7, with annotated localisation: Plasma membrane (supported) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, a matched rabbit IgG isotype control for the rabbit catalog antibody, and SLC9A1-knockout material as a biological negative (PB9151 tissue-IHC caption: rabbit primary). Check endogenous peroxidase and biotin background in kidney because the documented detection uses a biotinylated secondary, streptavidin–biotin complex and DAB (PB9151 tissue-IHC caption).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected PB9151 paraffin-section caption does not state the fixative (PB9151 tissue-IHC caption). That caption provides a starting IHC condition with heat retrieval in EDTA at pH 8.0 and 2 μg/ml primary antibody, but does not establish whether retrieval is essential (PB9151 tissue-IHC caption). No supplied comparison shows that frozen sections or IF are easier; for kidney chromogenic IHC, assess endogenous biotin and peroxidase background with the documented detection system (PB9151 tissue-IHC caption).
HPA tissue IHC evidence for SLC9A1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | High | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | High | Protein (IHC) | HPA → |
| Kidney | Collecting ducts | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Not detected | Protein (IHC) | HPA → |
| Liver | Cholangiocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SLC9A1 IHC Tips
Use the catalog antibody’s rat kidney IHC protocol as the starting point, then judge staining against SLC9A1’s expected membrane pattern (datasheet PB9151; UniProt P19634).
How should I troubleshoot weak SLC9A1 staining after antigen retrieval?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet PB9151). The catalog antibody’s rat kidney image used that retrieval, followed by 2 μg/ml primary antibody overnight at 4°C; its caption does not specify the fixative (datasheet PB9151). If staining is weak, check retrieval temperature and duration for consistency across sections before changing the primary antibody concentration (standard IHC practice). Compare a retrieved section with a no-retrieval section, and assess membrane staining in renal tubules rather than overall DAB darkness (HPA: abundant in renal tubules; UniProt P19634: cell membrane). Record any adjusted retrieval condition alongside the section’s fixation history (standard IHC practice).
Can the rat kidney image tell me which fixation preserves SLC9A1 best?
No fixative is reported for the catalog antibody’s paraffin-embedded rat kidney image, so target-specific fixation sensitivity is unknown (datasheet PB9151). The image supports staining after EDTA retrieval at pH 8.0, but cannot establish which fixation condition produced the section (datasheet PB9151). For a new specimen series, record fixative, fixation duration, processing schedule, and section age, then keep them consistent while comparing staining (standard IHC practice). Use matched positive-control sections in each run and judge both signal and tissue morphology (standard IHC practice). HPA tissue patterns and the protein’s membrane topology do not supply fixation-response data (HPA: tissue IHC profile; UniProt P19634 topology).
Where should convincing SLC9A1 staining appear in epithelial sections?
Look first for cell-membrane staining, particularly along the basolateral surface of epithelial cells (UniProt P19634: cell membrane and basolateral cell membrane). The annotated exception is choroid plexus epithelium, where SLC9A1 is luminal (UniProt P19634: subcellular location). HPA reports membranous staining across several tissues and high staining in kidney collecting ducts and intestinal glandular cells (HPA: tissue IHC profile). In chromogenic sections, compare the DAB distribution with cell boundaries and the counterstain, since crowded glands can make adjacent membranes appear diffuse (standard IHC practice). Interpret a predominantly nuclear pattern cautiously: HPA lists nucleoplasmic localisation as uncertain, while plasma-membrane localisation is supported (HPA: subcellular profile).
Can this IHC stain distinguish SLC9A1 isoforms or reveal a masked epitope?
Do not assign an isoform from chromogenic staining alone: the record lists 2 isoforms, but the supplied antibody caption gives no isoform-specific epitope (UniProt P19634: isoforms; datasheet PB9151). SLC9A1 has 13 transmembrane segments and a cytoplasmic C-terminal region spanning residues 506–815, so epitope position matters when interpreting membrane access (UniProt P19634 topology). Its annotated glycosylation sites lie at residues 42, 56, 61, 62, 68, and 75, while several phosphorylation sites occur in the C-terminal region (UniProt P19634: glycosylation and modified residues). If an epitope map becomes available, document its residue range and test retrieval with matched sections before attributing a staining difference to isoform expression (standard IHC practice).
How can I check the IHC pattern with multiplex IF?
Pair SLC9A1 with a validated marker for the expected cell population and inspect whether the signals occupy the same cells while remaining distinct at the membrane (HPA: high staining in kidney collecting ducts and intestinal glandular cells; UniProt P19634: cell membrane). Choose fluorophores after checking tissue autofluorescence and include single-stain controls to assess channel bleed-through (standard IF practice). Select permeabilisation according to the antibody’s mapped epitope: the N-terminal region is annotated extracellular, whereas residues 506–815 are cytoplasmic (UniProt P19634 topology). Because the supplied caption describes chromogenic paraffin-section IHC, establish IF fixation, permeabilisation, and antibody conditions separately (datasheet PB9151; standard IF practice). HPA’s supported plasma-membrane location provides a pattern check, while its additional nucleoplasmic location is uncertain (HPA: subcellular profile).
What should I check when SLC9A1 DAB staining is diffuse?
Inspect a no-primary control and reduce nonspecific secondary or detection signal before interpreting diffuse DAB as SLC9A1 (standard IHC practice). The catalog image used 10% goat serum, a biotinylated goat anti-rabbit secondary, a streptavidin-biotin complex, and DAB; reproduce those steps accurately when comparing runs (datasheet PB9151). Include an appropriate peroxidase block and assess whether the detection system contributes staining in a no-primary section (standard IHC practice). Titrate the primary around the caption’s 2 μg/ml condition if background persists, holding retrieval and development time constant (datasheet PB9151; standard IHC practice). Prioritise discrete membrane signal over uniform cytoplasmic haze when judging specificity (UniProt P19634: cell membrane; standard IHC practice).
How should I quantify SLC9A1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue compartment and scoring unit before comparing slides; renal collecting ducts and intestinal glandular cells have reported high staining (HPA: tissue IHC profile). For cell-based scoring, record the percentage of positive cells and membrane intensity, or use an H-score with a prespecified intensity scale (standard IHC practice). For area-based analysis, report membrane-positive area or positive-cell density per mm², using the same threshold and region-selection rules across sections (standard IHC practice). Normalise to the number of evaluable cells or viable tissue area, and exclude folds and damaged regions (standard IHC practice). Keep retrieval, DAB development, imaging, and counterstain consistent so technical variation does not dominate the comparison (standard IHC practice).
When is apparent SLC9A1 positivity likely to be artefact?
A convincing result should show membrane-enriched staining in an appropriate cell population, with basolateral localisation in most epithelia (UniProt P19634: subcellular location; HPA: membranous tissue expression). Check high-staining reference populations such as kidney collecting ducts against the study section, while allowing for differences in tissue and preparation (HPA: tissue IHC profile; standard IHC practice). Staining confined to section edges, folds, or necrotic regions warrants review for processing or detection artefact (standard IHC practice). Diffuse nuclear-only DAB should prompt a no-primary control and morphology review: HPA supports plasma-membrane localisation but calls its additional nucleoplasmic assignment uncertain (HPA: subcellular profile; standard IHC practice). Persistent no-primary signal calls for checking endogenous peroxidase and detection-system background before scoring the specimen (standard IHC practice).
Boster reagents
Best SLC9A1 / Sodium/hydrogen exchanger 1 IHC Antibodies
PB9151 has real SLC9A1 IHC images from paraffin sections of rat and mouse kidney and human mammary cancer tissue (PB9151 image captions). No IF image is supplied (PB9151 catalog).
Real IHC data
Anti-Sodium/Hydrogen Exchanger 1/SLC9A1 Antibody ®
Cat # PB9151
PB9151 is listed for IHC and WB in human, mouse and rat (PB9151 catalog). Its IHC captions document paraffin sections of rat and mouse kidney and human mammary cancer tissue (PB9151 image captions).
Which to pick: For tissue IHC, choose PB9151 for paraffin sections; its image captions document that processing, but do not report the fixative (PB9151 image captions). No SKU can be recommended for IF/ICC because PB9151 lists IHC and WB only and supplies no IF image (PB9151 catalog). For cross-species IHC, PB9151 lists human, mouse and rat reactivity and shows IHC images from all three species; it has a rabbit host, with clonality unreported (PB9151 catalog; PB9151 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P19634 (SL9A1_HUMAN, Sodium/hydrogen exchanger 1).
- Human Protein Atlas. SLC9A1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. SLC9A1 subcellular location (ICC-IF): Mainly localized to the plasma membrane. In addition localized to the nucleoplasm..
- Human Protein Atlas. SLC9A1 antibody validation summary (3 antibodies).
- Necrosis by sodium overload-associated genes TRPM4 and SLC9A1: biological roles and clinical implications in breast cancer progression. Frontiers in immunology 2025 — PMC12605240.
- Clinical relevance of macromolecular complexes involving integrins, potassium and sodium ion channels and the sodium/proton antiporter in human breast cancer. Cancer cell international 2025 — PMC11765915.
- Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival. eLife 2021 — PMC8282339.
- Roles of acid-extruding ion transporters in regulation of breast cancer cell growth in a 3-dimensional microenvironment. Molecular cancer 2016 — PMC4896021.
- PubMed PMID:2536298 — UniProt-cited evidence.
- PubMed PMID:2154036 — UniProt-cited evidence.
- PubMed PMID:1712287 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SLC9A1 (Sodium/hydrogen exchanger 1). Expected localisation Membranous in tissue (HPA tissue IHC); basolateral in most epithelia (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet PB9151). Validated IHC antibody: PB9151 at 0.5-1μg/ml recommended; image 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Colon (Glandular cells); negative Bone marrow. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded rat kidney tissue; fixative not specified (datasheet PB9151); 2. Fixation: Image fixative and duration unreported (datasheet PB9151); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet PB9151); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PB9151); 8. Primary antibody: Rabbit anti-SLC9A1, 0.5-1μg/ml recommended; image 2 μg/ml (datasheet PB9151); 9. Primary incubation: Overnight at 4 °C (datasheet PB9151). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Kidney staining is high in collecting ducts (HPA tissue IHC); Isoform / epitope: 2 isoforms; map the epitope to extracellular or cytoplasmic regions (UniProt); Regulation: Expression regulation not specified (UniProt). Evidence: UniProt P19634, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the plasma membrane. In addition localized to…, Datasheet PB9151, PMC12605240. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SLC9A1/immunohistochemistry-ihc-guide.